Updated between 11 March 2020 to 18 March 2020 to include reactions from stakeholders on the nomination of Daren Tang (Singapore) as Director General of the World Intellectual Property Organization (WIPO) Brook K. Baker, Senior Policy Analyst Health GAP (Global… Continue Reading
For more on KEI’s work on COVID-19, see keonline.org/coronavirus. The “Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020’’ will provide welcome funding to deal with the expanding COVID-19 pandemic. The current language on affordability (this Draft text), however, is worse… Continue Reading
Today, the Office of the United States Trade Representative hosted the hearing for the annual Special 301 Review. The review process includes a solicitation of written comments and hearing testimony, and results in the publication of the Special 301 Report.… Continue Reading
Filed in 84 FR 68128, Docket No. 191126-0092. KEI-NIST-RFC-iEdison, 27Jan2020 January 27, 2020 Dr. Courtney Silverthorn Deputy Director, Technology Partnerships Office, National Institute of Standards and Technology Technology Partnerships Office 100 Bureau Drive, MS 2200, Gaithersburg, MD 20899, mailto:courtney.silverthorn@nist.gov Re:… Continue Reading
On 20 May 2019, the World Intellectual Property Organization (WIPO) convened an International Conference on Intellectual Property (IP) and Development. On 19 November 2019, at the 24th session of WIPO’s Committee on Development and Intellectual Property (CDIP), Knowledge Ecology International… Continue Reading
On Thursday, 3 October 2019, Knowledge Ecology International delivered the following statement on Agenda item 16, Report on the SCP. As part of the WIPO Secretariat’s review of existing research on patents and access to medical products and health technologies,… Continue Reading
The UK Labour Party Document, “Medicines-For-The-Many” is 52 pages long, including 9 pages of end notes. It is an ambitious document. The document discusses, in some detail, innovation as well as access and affordability. The reforms proposed include measures that… Continue Reading
(UPDATE: As noted in the comments below, the NIH provided a response to the joint comments submitted on September 5, 2019, well in advance of the close of the comment period on September 15, 2019) On September 19, 2019, Knowledge… Continue Reading
Zolgensma is a gene therapy for spinal muscular atrophy (SMA) that was approved by the US FDA in May 2019, at a price of $2.1 million per patient. Zolgensma was licensed from a children’s hospital where it was developed on… Continue Reading
KEI Briefing Note 2019:1 International Reference Pricing August 22, 2019 International Reference Pricing, often referred to as External Reference Pricing (ERP), is the practice of using a price in a foreign market as a benchmark for an acceptable price in… Continue Reading